Skip to main content

Halaven Disease Interactions

There are 6 disease interactions with Halaven (eribulin).

Major

Antineoplastics (applies to Halaven) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories PROD (2002):
  2. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb PROD (2001):
  3. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb PROD (2001):
  4. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation PROD (2001):
  5. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb PROD (2001):
  6. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb PROD (2001):
  7. "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) PROD (2001):
  8. "Product Information. Fludara (fludarabine)." Berlex Laboratories PROD (2001):
  9. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
  10. "Product Information. Matulane (procarbazine)." Roche Laboratories PROD (2001):
  11. "Product Information. DTIC-Dome (dacarbazine)." Bayer PROD (2001):
  12. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
  13. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc PROD (2001):
  14. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
  15. "Product Information. Hycamtin (topotecan)." SmithKline Beecham PROD (2001):
  16. "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer PROD (2001):
  17. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb PROD (2001):
  18. "Product Information. Nipent (pentostatin)." Hospira Inc PROD (2001):
  19. "Product Information. Tabloid (thioguanine)." Prasco Laboratories PROD (2001):
  20. "Product Information. Xeloda (capecitabine)." Roche Laboratories PROD (2001):
  21. "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
  22. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome PROD (2001):
  23. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  24. "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
  25. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
  26. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation PROD (2001):
  27. "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
  28. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
  29. "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
View all 29 references
Moderate

Eribulin (applies to Halaven) cytopenias

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia, Thrombocytopenia

Adverse hematologic effects including neutropenia, and febrile neutropenia (fever >=38.5°C with Grade 3 or 4 neutropenia) have been associated with the use of eribulin. It is recommended to monitor complete blood counts prior to each dose and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration of therapy and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting longer than 7 days. Do not administer therapy on Day 1 or Day 8 if ANC < 1,000/mm3, platelets < 75,000/mm3, or grade 3 or 4 non-hematological toxicities.

References

  1. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
Moderate

Eribulin (applies to Halaven) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Pharmacokinetics studies to evaluate the effect of hepatic impairment in patients treated with eribulin demonstrated that patients with mild hepatic impairment (Child-Pugh A) and moderate hepatic impairment (Child-Pugh B) had higher eribulin exposures as compared to patients with normal hepatic function. It is recommended to reduce the starting dose of eribulin in patients with mild or moderate hepatic impairment according to the manufacturer recommendations. Eribulin has not been studied in patients with severe hepatic impairment (Child-Pugh C). Caution and close monitoring should be taken.

References

  1. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
Moderate

Eribulin (applies to Halaven) peripheral neuropathy

Moderate Potential Hazard, Moderate plausibility.

In clinical trials, eribulin caused peripheral neuropathy. Monitor patients closely for signs of peripheral motor and sensory neuropathy. It is recommended to withhold treatment in patients who experience Grade 3 or 4 peripheral neuropathy, until resolution to Grade 2 or less.

References

  1. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
Moderate

Eribulin (applies to Halaven) QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hypokalemia, Magnesium Imbalance, Electrolyte Abnormalities, Arrhythmias

In clinical trials, eribulin has caused QT prolongation independent of concentration. Close monitoring should be exercised in patients with congestive heart failure, bradyarrhythmias, those taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities. It is recommended to correct hypokalemia or hypomagnesemia prior to starting therapy and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.

References

  1. "Product Information. Halaven (eribulin)." Eisai Inc (2010):
Moderate

Eribulin (applies to Halaven) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Pharmacokinetics studies to evaluate the effect of renal impairment in patients treated with eribulin demonstrated that patients with moderate and severe renal impairment had higher eribulin dose-normalized exposures compared to that in patients with normal renal function. It is recommended to reduce the starting dose of eribulin in patients with moderate or severe renal impairment (CrCL 15-49 mL/min) according to the manufacturer recommendations.

References

  1. "Product Information. Halaven (eribulin)." Eisai Inc (2010):

Halaven drug interactions

There are 479 drug interactions with Halaven (eribulin).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer